Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

;

The data from this abstract demonstrated that RB006 (1mg/kg, IV) results in consistent and near complete inhibition of FIX in patients with ACS with stable anti-coagulation throughout catheterization (PCI).  These findings further validate the dosing of RB006 for Regado's ongoing and planned clinical trials.

The abstract is coauthored by Thomas J. Povsic, MD, Ph.D., Richard A. Becker, MD, and John H. Alexander, MD, MHS, all from Duke University Medical Center; Christopher P. Rusconi, Ph.D., Steven L. Zelenkofske, D.O., both from Regado Biosciences; and William Wargin, Ph.D., President of PK-PM Associates, LLC; Mauricio G. Cohen, MD, University of Miami Miller School of Medicine; Roxana Mehran, MD, Mount Sinai School of Medicine; Christoph Bode, MD, University of Freiburg, Germany; Joshua Krasnow, MD, Heart Center Research, LLC; and Merrill Krolick, D.O., Heart and Vascular Institute of Florida.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1,
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Maine , Dec. 22, 2014  Mark ... analysis brief providing a summary of the 2015 ... plan enrollment trends.  According to ... for Planning and Evaluation, Department of Health and ... were enrolled in individual medical plans through the ...
(Date:12/22/2014)... TAIPEI , Dec. 22, 2014 ... received Notice of Allowance for AC-201, TWi Biotechnology,s ... Office in China for ... or its pharmaceutically acceptable salts, active metabolite for ... covers the methods of treatment using AC-201 for ...
(Date:12/19/2014)... , Dec. 19, 2014 You,re visiting the ... and cleaning when he or she says you need ... heard before, you may have several questions and feel ... relieved to know it,s nothing to worry about. The ... questions and alleviate any anxiety the public may have ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... pharmaceutical products - particularly those that are first-in-class, socially ... not only external disease state communication but also internal ... a product for a new or relatively unknown condition ... the new disease before introducing a new product to ...
... Company (NYSE: LLY ) today announced that the ... a prior ruling by the U.S. District Court for the ... the company,s method-of-use patent on Strattera® (atomoxetine). In the case ... et al, the court ruled in favor of Lilly, ...
Cached Medicine Technology:Building Support for a New Product Through Effective Internal Disease State Communication 2U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent 2
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... Ill. (PRWEB) December 21, 2014 ... recommendations for chest computed tomography (CT) to evaluate ... relevant findings, including cancer, according to a new ... , Researchers said the findings show that radiologist ... represent valuable contributions to patient care. , RAIs, ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 In ... is segmented by power source, product, and application. ... electric-powered, battery-powered, and pneumatic instruments. By product, the ... and accessories segments. The handpieces market is further ... devices, suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, ...
(Date:12/21/2014)... Beverly Hills, Ca (PRWEB) December 21, 2014 ... Dr. Khanna was a guest at the Aspen Helicopters ... for kids and a Santa with sleigh, flown by ... the helicopter appeared invisible; only Santa with sleigh was ... both during day and night. Dr.Khanna has helped many ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Faced with a barrage of pressing issues, the ... agenda. The timing bodes well for change, according ... University Center for Health Policy and Professionalism, associate professor ... a pediatrician at Riley Hospital for Children. , "If ...
... Feb. 6 Turner Construction Company, the nation,s leading ... Northern Inyo Hospital to proceed with the $42 million ... for Phase Two will start in March 2009 with ... of a new central plant, emergency rooms, ICU, CCU, ...
... Colo., Feb. 6 Baxa Corporation, an Englewood Colorado-based medical ... of the Top 50 Family-Owned Companies in Colorado. Qualifying ... be controlled by a single family, and controlling family members ... has to have been involved in the company for at ...
... Medical Group Inc.,(OTC Bulletin Board: WMDG; "Winner Medical"), ... and wound care products) in China, today,announced that ... first quarter,ended December 31, 2008 on Friday, February ... The earnings release will be available on the ...
... (Nasdaq: EVVV ) will release its 2008 fourth ... 2009 on Tuesday, Febuary 24, 2009, before regular market trading ... same day at 7:30 a.m. Central Time (8:30 a.m. Eastern ... full-year operating results and future outlook, followed by a question ...
... ... Brookfield, Wisconsin (PRWEB) February 6, 2009 -- Watching your weight? ... International Foundation of Employee Benefits Plans found that of those ... loss program., , ,When asked their primary reason for offering a ...
Cached Medicine News:Health News:Prioritizing health-care reform components 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 3Health News:Winner Medical Schedules 2008/2009 First Quarter Earnings Release on Friday, February 13, 2009 2Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: